Pieris Publication Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies. SITC 2019.
Pieris Publication Bruns IB, Fitzgerald MF, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Jiang F, Lickliter J, Close DR5 Phase 1 evaluation of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Rα Abstract: OA5336
Pieris Publication Bruns IB, Fitzgerald MF, Mensing G, Tsung M, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Olsson M, Ghobadi C, Walsh O, McLendon K, Farinola N, Hatchuel L, Close DR. Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma.
Pieris Publication Multiple ascending dose study of the inhaled IL-4Rα antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma
Pieris Publication Bruns IB, Fitzgerald MF, Pardali K, Gardiner P, Keeling DJ, Axelsson LT, Jiang F, Lickliter J, Close DR. First-in-human data for the inhaled IL-4Rα antagonist AZD1402/PRS-060 reveals a promising clinical profile for the treatment of asthma.
Pieris Publication Birgit Bossenmaier, Corinna Schlosser, Rachida-Siham Bel Aiba, Eva-Maria Hansbauer, Thomas Jaquin, Christian Barthels, Janet Peper, Markus Zettl, Benjamin Weiche, Thibaut Angevin, Michelle Yegres, Reno Winter, Stefan Grüner, Christine Rothe, Shane A. Olwill. Costimulatory T-cell engagement by PRS-342, a GPC3/4-1BB bispecific molecule, leads to activation of T cells and tumor growth inhibition in a HCC humanized mouse model.
Pieris Publication Marina Pavlidou, Janet Peper, Lucia Pattarini, Christian Barthels, Eva-Maria Hansbauer, Rachida Bel Aiba, Milan Blanusa, Alix Scholer-Dahirel, Maximilien Grandclaudon, Céline Grand, Jamila Elhmouzi-Younes, Matthieu Rivière, VéroniqueBlanc, Christine Rothe, Shane Olwill. Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/ONC0055, a 4-1BB / PD-L1 bispecific compound for tumor localized activation of the immune system.
Pieris Publication Katerina Pardali, Fanyi Jiang, Mary Fitzgerald, Gabriele Matschiner, David Keeling. AZD1402/PRS-060, an inhaled Anticalin IL-4Ra antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies.
Pieris Publication Marlon J. Hinner, Rachida-Siham Bel Aiba, Corinna Schlosser, Thomas Jaquin, Andrea Allersdorfer, Sven Berger, Alexander Wiedenmann, Gabriele Matschiner, Julia Schüler, Ulrich Moebius, Christine Rothe, Shane A. Olwill Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and tumor-localized CD8(+) T cell expansion in a humanized mouse model
Pieris Publication Marlon J. Hinner, Rachida-Siham Bel Aiba, Thomas Jaquin, Sven Berger, Manuela Dürr, Corinna Schlosser, Andrea Allersdorfer, Christine Rothe, Louis A. Matis, Shane A. Olwill Preclinical toxicology and pharmacology for the 4-1BB/HER2 bispecific PRS-343: A first-in-class costimulatory T cell engager
